Results 161 to 170 of about 5,710 (181)

Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis

European Heart Journal - Cardiovascular Pharmacotherapy, 2020
Anton Camaj, Michel Zeitouni
exaly  

LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial

European Journal of Preventive Cardiology, 2021
Ioanna Gouni-Berthold, Marc S Sabatine, Michelle L O'Donoghue   +2 more
exaly  

Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis

Stroke, 2020
Jeffrey L. Saver, Marc S Sabatine, Anthony C Keech   +2 more
exaly  

Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.

Journal of the American College of Cardiology, 2014
Mats Eriksson, Evan A Stein, Marc S Sabatine   +2 more
exaly  

Effect of Evolocumab on Atherogenic Lipoproteins During the Peri- and Early Postinfarction Period

Circulation, 2020
Michael J Blaha, Steven P Jones, Gary Gerstenblith   +2 more
exaly  

Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia

Journal of the American College of Cardiology, 2019
Marc S Sabatine, Stephen Wiviott, Frederick J Raal   +2 more
exaly  

Cost-effectiveness of Evolocumab

Revista Española de Cardiología (English Edition), 2018
Carlos, Escobar, Vivencio, Barrios
openaire   +2 more sources

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease

Circulation, 2018
Basil S. Lewis, Marc S Sabatine
exaly  

Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

Journal of the American College of Cardiology, 2014
Erik Stroes, Leslie Cho
exaly  

Alirocumab/evolocumab

Reactions Weekly, 2021
openaire   +1 more source